Moberg Pharma AB (FRA:MB8) E10: €2.49 (As of Mar. 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
59 GF Score
Price €0.79
GF Value €1.09
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB E10?

Moberg Pharma AB FRA:MB8 -2.95% 59 E10 is €2.49 as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.09. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Moberg Pharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.003. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €2.49 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Moberg Pharma AB's average E10 Growth Rate was -4.20% per year. During the past 3 years, the average E10 Growth Rate was 1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Moberg Pharma AB was 1.00% per year. The lowest was 1.00% per year. And the median was 1.00% per year.

As of today (2026-06-26), Moberg Pharma AB's current stock price is €0.789. Moberg Pharma AB's E10 for the quarter that ended in Mar. 2026 was €2.49. Moberg Pharma AB's Shiller PE Ratio of today is 0.32.

During the past 13 years, the highest Shiller PE Ratio of Moberg Pharma AB was 18.76. The lowest was 0.15. And the median was 0.64.


Moberg Pharma AB  (FRA:MB8) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Moberg Pharma AB's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=0.789/2.49
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Moberg Pharma AB was 18.76. The lowest was 0.15. And the median was 0.64.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Moberg Pharma AB E10 Related Terms


Moberg Pharma AB E10 Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB E10 Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.95 2.40 2.81 2.52

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 2.51 2.57 2.58 2.49

FRA:MB8 vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Shiller PE Ratio falls into.


FRA:MB8
59GF Score
Moberg Pharma AB FRA:MB8
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Moberg Pharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.003/133.3862*133.3862
=-0.003

Current CPI (Mar. 2026) = 133.3862.

Moberg Pharma AB Quarterly Data

per share eps CPI Adj_EPS
201512 0.000 100.276 0.000
201603 -0.245 100.751 -0.324
201606 1.196 101.019 1.579
201609 0.529 101.138 0.698
201612 -0.117 102.022 -0.153
201703 -0.101 102.022 -0.132
201706 -0.263 102.752 -0.341
201709 0.423 103.279 0.546
201712 0.315 103.793 0.405
201803 0.067 103.962 0.086
201806 0.149 104.875 0.190
201809 0.065 105.679 0.082
201812 0.349 105.912 0.440
201903 17.321 105.886 21.819
201906 1.874 106.742 2.342
201909 0.937 107.214 1.166
202003 -0.107 106.563 -0.134
202006 -0.172 107.498 -0.213
202009 -0.154 107.635 -0.191
202103 0.297 108.360 0.366
202106 -0.053 108.928 -0.065
202109 -0.059 110.338 -0.071
202112 -0.065 112.486 -0.077
202203 -0.063 114.825 -0.073
202206 -0.039 118.384 -0.044
202209 -0.027 122.296 -0.029
202212 -0.014 126.365 -0.015
202303 -0.030 127.042 -0.031
202306 -0.022 129.407 -0.023
202309 -0.030 130.224 -0.031
202312 -0.021 131.912 -0.021
202403 -0.020 132.205 -0.020
202406 -0.012 132.716 -0.012
202409 -0.003 132.304 -0.003
202412 -0.453 132.987 -0.454
202503 -0.005 132.825 -0.005
202506 -0.015 133.699 -0.015
202509 -0.008 133.482 -0.008
202512 -0.025 133.386 -0.025
202603 -0.003 133.386 -0.003

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €2.49 mean?
Moberg Pharma AB (FRA:MB8) has a E10 of €2.49 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's E10 too high?
Moberg Pharma AB's current E10 is €2.49. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's E10 compare to ZTS?
Moberg Pharma AB's E10 of €2.49 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current E10 is €2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current E10 of €2.49. The stock's GF Value™ is €1.09, compared to a current price of €0.79 — trading 27.6% below its estimated fair value. The current E10 is €2.49. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current E10 is €2.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.79 is trading 27.6% below its estimated GF Value™ of €1.09.

Key valuation signals for FRA:MB8:

  • E10: €2.49
  • GF Value™: €1.09 vs. price of €0.79 (27.6% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for FRA:MB8

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.79
Price
€1.09
GF Value